Feb 18, 2026 08:01AM
Feb 18, 2026 08:00AM
Jan 20, 2026 08:01AM
Jan 20, 2026 08:00AM
Jan 19, 2026 12:20PM
Jan 12, 2026 08:01AM
Jan 12, 2026 08:00AM Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Dec 16, 2025 08:00AM
Dec 16, 2025 08:00AM
Nov 18, 2025 08:01AM
Nov 18, 2025 08:00AM
Nov 6, 2025 08:00AM
Nov 4, 2025 08:00AM
Sep 30, 2025 08:01AM Lipocine reports one-third enrollment in postpartum depression trial
Sep 30, 2025 08:00AM
Sep 5, 2025 04:30PM
Aug 26, 2025 08:00AM
Aug 5, 2025 08:00AM
Jun 30, 2025 06:53AM
Jun 26, 2025 08:04AM
Jun 26, 2025 08:00AM Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression
Jun 23, 2025 08:00AM
Jun 10, 2025 06:41AM
Jun 9, 2025 08:02AM
Jun 9, 2025 08:00AM
May 22, 2025 08:00AM
May 14, 2025 08:00AM
May 8, 2025 08:00AM Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025
May 6, 2025 08:07AM
May 6, 2025 08:00AM
Mar 26, 2025 08:00AM
Mar 13, 2025 08:00AM
Mar 12, 2025 08:00AM
Feb 6, 2025 08:03AM
Feb 6, 2025 08:00AM Lipocine Receives Updated Regulatory Guidance on LPCN 1154
Dec 17, 2024 08:01AM
Dec 17, 2024 08:00AM
Nov 18, 2024 08:00AM
Nov 7, 2024 08:00AM
Oct 31, 2024 08:01AM
Oct 31, 2024 08:00AM
Oct 10, 2024 08:02AM Lipocine (LPCN) Announces Positive Oral Brexanolone Quantitative EEG Results
Oct 10, 2024 08:00AM
Oct 8, 2024 08:02AM
Oct 8, 2024 08:00AM
Oct 2, 2024 08:00AM
Sep 30, 2024 08:00AM
Sep 5, 2024 08:00AM
Aug 27, 2024 08:00AM Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference
Aug 8, 2024 08:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All